Evidence map›Paper›PMID 40492696›Full record

ReviewCancer biology & medicine2025

The mechanisms and clinical significance of CD8

Tao Zhong, Shuo Sun, Mingsheng Zhao, Bin Zhang, Huabao Xiong

Abstract readReview
In one paragraph

Review in Cancer biology & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. DUSP4 promotes anti-tumor CD8Nature communications · 2026
    Article
  5. Article
  6. Review
  7. International journal of molecular sciences · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tao Zhong *Institute of Immunology and Molecular Medicine, Key Laboratory of Cell and Biomedical Technology of Shandong Province, College of Basic Medicine, Jining Medical University, Jining 272067, China.ORCID 0000-0003-3898-057X
Shuo Sun *College of Life Science, Jining Medical University, Rizhao 276826, China.
Mingsheng ZhaoInstitute of Immunology and Molecular Medicine, Key Laboratory of Cell and Biomedical Technology of Shandong Province, College of Basic Medicine, Jining Medical University, Jining 272067, China.
Bin ZhangAffiliated Hospital of the Jining Medical University, Jining 272029, China.
Huabao XiongInstitute of Immunology and Molecular Medicine, Key Laboratory of Cell and Biomedical Technology of Shandong Province, College of Basic Medicine, Jining Medical University, Jining 272067, China.ORCID 0000-0003-0180-2104

Funding

National Natural Science Foundation of China 82171810Program of Shandong Provincial Scientific and Technological Development of Traditional Chinese Medicine M-2023210
6 · The paper itself

Abstract

CD8

Indexed as

CD8-Positive T-LymphocytesNeoplasmsAnimalsClinical RelevanceEpigenesis, GeneticHumansImmunotherapyT-Cell ExhaustionTumor Microenvironmentanti-tumor immunitycancer immunotherapyCD8immune checkpointimmune checkpoint inhibitors

Identifiers

PMID40492696
PMCPMC12240197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.